Targeting the STAT3 pathway with STAT3 degraders
Trends in Pharmacological Sciences · 2024-09 · 45 (9) · 811-823
DOI: 10.1016/j.tips.2024.07.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Pharmacological Sciences, 2024-09. Verfasst von Zhijie Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Key Laboratory of Viral Oncology, Ministry of Science and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen 518100, China…. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Proteolysis. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: Tianjin Postdoctoral Science Foundation, Shenzhen Hospital, Southern Medical University, Shenzhen Key Laboratory of Synthetic Genomics.
Abstract (Originalsprache)
Signal transducer and activator of transcription 3 (STAT3) has been widely considered as a therapeutic target for various diseases, especially tumors. Thus far, several STAT3 inhibitors have been advanced to clinical trials; however, the development of STAT3 inhibitors is hindered by numerous dilemmas. Fortunately, STAT3 degraders represent an alternative and promising strategy to block STAT3, attracting extensive research interest. Here, we analyze the recent advancements of STAT3 degraders, including proteolysis targeting chimeras (PROTACs) and small-molecule natural products, focusing on their structures, mechanisms, and biological activities. We discuss the potential opportunities and challenges for developing STAT3 degraders. It is hoped that this Review will provide insights into the discovery of potent STAT3-targeting drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shenzhen Key Laboratory of Viral Oncology, Ministry of Science and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen 518100, China; Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key…
- Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
- Shenzhen Key Laboratory of Viral Oncology, Ministry of Science and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen 518100, China. Electronic address: guoxia0504_sz@163.com.
- Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China. Ele…
Förderung
- Tianjin Postdoctoral Science Foundation
- Shenzhen Hospital, Southern Medical University
- Shenzhen Key Laboratory of Synthetic Genomics
- Thousand Young Talents Program of China
- Science and Technology Innovation as a Whole Plan Projects of Shaanxi Province
- Science, Technology and Innovation Commission of Shenzhen Municipality
- Shandong Key Laboratory of Disease Control in Mariculture
- Southern Medical University
Zitieren
APA
Wang, Z., Liao, X., He, H., Guo, X., & Chen, J. (2024). Targeting the STAT3 pathway with STAT3 degraders. Trends in Pharmacological Sciences, 45(9), 811-823. https://doi.org/10.1016/j.tips.2024.07.003
Vancouver
Wang Z, Liao X, He H, Guo X, Chen J. Targeting the STAT3 pathway with STAT3 degraders. Trends in Pharmacological Sciences. 2024;45(9):811-823. doi:10.1016/j.tips.2024.07.003
BibTeX
@article{Wang2024,
author = {Wang, Zhijie and Liao, Xiaotong and He, Haiqi and Guo, Xia and Chen, Jianjun},
title = {Targeting the STAT3 pathway with STAT3 degraders},
journal = {Trends in Pharmacological Sciences},
year = {2024},
volume = {45},
number = {9},
pages = {811--823},
doi = {10.1016/j.tips.2024.07.003}
}
EUVIMED